Cargando…

Investigating the Association Between Baseline Characteristics (HbA1c and Body Mass Index) and Clinical Outcomes of Fast-Acting Insulin Aspart in People with Diabetes: A Post Hoc Analysis

INTRODUCTION: The aim of this study was to investigate the association between baseline characteristics [HbA1c and body mass index (BMI)] and the effect of mealtime fast-acting insulin aspart (faster aspart) relative to insulin aspart (IAsp) or basal-only insulin therapy on several efficacy and safe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bowering, Keith, Rodbard, Helena W., Russell-Jones, David, Bode, Bruce, Harris, Stewart, Piletic, Milivoj, Heller, Simon, Woo, Vincent, Babu, Vinay, Dethlefsen, Claus, Mathieu, Chantal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349278/ https://www.ncbi.nlm.nih.gov/pubmed/30547388 http://dx.doi.org/10.1007/s13300-018-0553-7

Ejemplares similares

Adding fast‐acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18‐week, open‐label, phase 3 trial (onset 3)
por: Rodbard, Helena W., et al.
Publicado: (2017)

Baseline nocturnal glucose change: A predictor of the treatment effect of bolus intensification in insulin‐treated type 2 diabetes
por: Peters, Anne L., et al.
Publicado: (2019)

Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial
por: Franek, Edward, et al.
Publicado: (2022)

Mealtime fast‐acting insulin aspart versus insulin aspart for controlling postprandial hyperglycaemia in people with insulin‐resistant Type 2 diabetes
por: Bowering, K., et al.
Publicado: (2018)

Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis
por: Yu, Miao, et al.
Publicado: (2020)

Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD‐11
por: Frias, Juan P., et al.
Publicado: (2021)

Should Studies of Diabetes Treatment Stratification Correct for Baseline HbA1c?
por: Jones, Angus G., et al.
Publicado: (2016)

The effect of basal–bolus therapy varies with baseline 1,5‐anhydroglucitol level in people with Type 2 diabetes: a post hoc analysis
por: Heller, S., et al.
Publicado: (2018)

Effect of once‐weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c
por: Gallwitz, Baptist, et al.
Publicado: (2017)

Measurement of HbA(1c) and HbA(2) by Capillarys 2 Flex Piercing HbA(1c) programme for simultaneous management of diabetes and screening for thalassemia
por: Ke, Peifeng, et al.
Publicado: (2017)

Standardization of the HbA(2) Assay
por: Paleari, Renata, et al.
Publicado: (2018)

Change in HbA(1c) Across the Baseline HbA(1c) Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents
por: Gentilella, Raffaella, et al.
Publicado: (2019)

Influence of Baseline HbA1c and Antiplatelet Therapy on 1-Year Vein Graft Outcome
por: Zhu, Yunpeng, et al.
Publicado: (2022)

One Drop | Mobile on iPhone and Apple Watch: An Evaluation of HbA1c Improvement Associated With Tracking Self-Care
por: Osborn, Chandra Y, et al.
Publicado: (2017)

HbA(1c): The lower the better?
por: Araki, Eiichi, et al.
Publicado: (2011)

The True Value of HbA1c as a Predictor of Diabetic Complications: Simulations of HbA1c Variables
por: Lind, Marcus, et al.
Publicado: (2009)

Haemoglobin J-Baltimore can be detected by HbA(1c) electropherogram but with underestimated HbA(1c) value
por: Brunel, Valéry, et al.
Publicado: (2016)

Effective Overall Glycaemic Control with Fast-Acting Insulin Aspart Across Patients with Different Baseline Characteristics: A Post Hoc Analysis of the Onset 9 Trial
por: Lane, Wendy, et al.
Publicado: (2022)

Influence of Serum Albumin on HbA1c and HbA1c-Defined Glycemic Status: A Retrospective Study
por: Feng, Xiaojing, et al.
Publicado: (2021)

Efficacy and safety of fast‐acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52‐week, randomized, treat‐to‐target, phase III trial
por: Mathieu, Chantal, et al.
Publicado: (2018)

Hb H Interference on Measurement Of HbA1c With Ion-Exchange HPLC
por: Agilli, Mehmet, et al.
Publicado: (2013)

Drugs affecting HbA1c levels
por: Unnikrishnan, Ranjit, et al.
Publicado: (2012)

Current Status of HbA1c Biosensors
por: Lin, Hua, et al.
Publicado: (2017)

Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus
por: Haahr, Hanne, et al.
Publicado: (2018)

Hemoglobin variants detected by hemoglobin A1c (HbA1c) analysis and the effects on HbA1c measurements
por: Nasir, Nadzimah Mohd, et al.
Publicado: (2010)

In-House Algorithm for Reporting Discrepant HbA1c Result and Troubleshooting a Case of False Low HbA1c
por: Pant, Vivek, et al.
Publicado: (2021)

Estimation of mean erythrocyte age using HbA1c or HbA1c/glycated albumin for evaluation of anemia severity
por: Koga, Masafumi, et al.
Publicado: (2023)

Slope of change in HbA(1c) from baseline with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2018)

Differential Thermal Stability and Oxidative Vulnerability of the Hemoglobin Variants, HbA(2) and HbE
por: Chakrabarti, Abhijit, et al.
Publicado: (2013)

Significantly High HbA(1c) in Diabetic Patient with Hb J: Case Report
por: Wan Nik, Wan Nor Fazila Hafizan, et al.
Publicado: (2022)

Low HbA2 Level in β-Thalassemia Trait
por: ÖZSOYLU, Şinasi
Publicado: (2013)

HbA(1c) measurement and relationship to incident stroke
por: Robson, R., et al.
Publicado: (2016)

Very low HbA1C, is it a problem?
por: Joob, Beuy, et al.
Publicado: (2018)

Engineering of the endogenous HBD promoter increases HbA2
por: Boontanrart, Mandy Y, et al.
Publicado: (2023)

Visit-to-visit HbA1c variability is inversely related to baroreflex sensitivity independently of HbA1c value in type 2 diabetes
por: Matsutani, Daisuke, et al.
Publicado: (2018)

Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes
por: Danne, Thomas, et al.
Publicado: (2019)

Association of visit-to-visit HbA1c variability with cardiovascular diseases in type 2 diabetes within or outside the target range of HbA1c
por: Sun, Bao, et al.
Publicado: (2022)

An Evaluation of Point-of-Care HbA1c, HbA1c Home Kits, and Glucose Management Indicator: Potential Solutions for Telehealth Glycemic Assessments
por: Zaharieva, Dessi P., et al.
Publicado: (2022)

A Post Hoc Analysis of HbA1c, Hypoglycemia, and Weight Change Outcomes with Alogliptin vs Glipizide in Older Patients with Type 2 Diabetes
por: Bron, Morgan, et al.
Publicado: (2014)

Correlation Between Time in Range and HbA1c in People with Type 2 Diabetes on Basal Insulin: Post Hoc Analysis of the SWITCH PRO Study
por: Goldenberg, Ronald M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nb9ur7ssjv5mcv9ljuv0kn1v3l